Idiopathic pulmonary hypertension: What did we learn from genes?

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 22, Issue SUPPL. 1, 2005, Pages

  Sztrymf, Benjamin ^a   Yaïci, Azzedine ^a   Jaïs, Xavier ^a   Sitbon, Olivier ^a   Simonneau, Gerald ^a   Humbert, Marc ^a  

^a HÔPITAL ANTOINE BÉCLÈRE   (France)

Author keywords

ALK 1; BMPR2; Endoglin; Hereditary hemorrhagic telangiectasia; Primary pulmonary hypertension; Pulmonary arterial hypertension; TGF

Indexed keywords

ANOREXIGENIC AGENT; BONE MORPHOGENETIC PROTEIN; ENDOGLIN; RECEPTOR PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

BMPR2 GENE; CELL PROLIFERATION; CLUSTER ANALYSIS; CONFERENCE PAPER; DISEASE CLASSIFICATION; FAMILY HISTORY; GENE; GENE MUTATION; GENE THERAPY; GENETIC ANALYSIS; GENETIC COUNSELING; GENETIC PREDISPOSITION; GENOMICS; GERM LINE; HUMAN; IDIOPATHIC DISEASE; MULTIGENE FAMILY; PATHOGENESIS; PENETRANCE; PHARMACOGENETICS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RENDU OSLER WEBER DISEASE;

BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; FEMALE; GENE THERAPY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTENSION, PULMONARY; MALE; MUTATION; PEDIGREE; PROGNOSIS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

EID: 31544450578     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (51)

1. Runo JR, Loyd JE: Primary pulmonary hypertension. Lancet 2003; 361: 1533-44.
2. Humbert M, Morrell NW, Archer SL, et al: Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 13S-24S.
3. Simonneau G, Galie N, Rubin LJ, et al: Clinical classification of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 5S-12S.
4. Humbert M, Sitbon O, Simonneau G: Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425-36.
5. Dresdale DT, Mitchum RJ, Schultz M: Recent studies in primary pulmonary hypertension, including pharmacodynamic observations on pulmonary vascular resistance. Bull NY Acad Med 1954; 30: 195-207.
6. Loyd JE, Primm RK, Newman JH: Familial primary pulmonary hypertension. Clinical patterns. Am Rev Respir Dis 1984; 129: 194-7.
7. Rich S, Dantzker DR, Ayres SM, et al: Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987; 107: 216-23.
8. Loyd JE, Butler MG, Foroud TM, et al: Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension. Am J Respir Crit Care Med 1995; 152: 93-7.
9. Nichols WC, Koller DL, Slovis B, et al: Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31-32. Nat Genet 1997; 15: 277-80.
10. The International PPH Consortium: Lane KB, Machado RD, Pauciulo MW, et al: Heterozygous germline mutations in a TGF-β receptor, BMPR2, are the cause of familial primary pulmonary hypertension. Nat Genet 2000; 26: 81-4.
11. Deng Z, Morse JH, Slager SL, et al: Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenctic protein receptor-II gene. Am J Hum Genet 2000; 67: 737-44.
12. Massague J, Chen YG: Controlling TGFβ signaling. Genes Dev 2000; 14: 627-44.
13. Wilkins MR, Gibbs JSR, Shovlin CL: A gene for primary pulmonary hypertension. Lancet 2000; 356: 1207-8.
14. Loscalzo J: Genetic clues to the cause of primary pulmonary hypertension. N Engl J Med 2001; 345: 367-71.
15. Machado RD, Pauciulo MW, Thomson JR, et al: BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet 2001; 68: 92-102.
16. Nishihara A, Watabe T, Imamura T, Miyazono K: Functional heterogeneity of bone morphogenetic protein receptor-II mutants found in patients with primary pulmonary hypertension. Mol Biol Cell 2002; 13: 3055-63.
17. Humbert M, Deng Z, Simonneau G, et al: BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives. Eur Respir J 2002; 20: 518-23.
18. Yeager ME, Halley GR, Golpon HA, Voelkel NF, Tuder RM: Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension. Circ Res 2001; 88: e2-e11.
19. Machado RD, James V, Southwood M, et al: Investigation of second genetic hits at the BMPR2 locus as a modulator of disease progression in familial pulmonary arterial hypertension. Circulation 2005; 111: 607-13.
20. Yuan JXJ, Rubin LJ: Pathogenesis of pulmonary arterial hypertension: the need for multiple hits. Circulation 2005; 111: 534-8.
21. Humbert M, Nunes H, Sitbon O, Parent F, Hervé P, Simonneau G: Risk factors for pulmonary arterial hypertension. Clin Chest Med 2001; 22: 459-75.
22. Sztrymf B, Francoual J, Sitbon O, et al: Clinical, haemodynamic and genetic features of familial pulmonary hypertension. Rev Mal Respir 2004; 21: 909-15.
23. Morrell NW, Yang X, Upton PD, et al: Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-β1 and bone morphogenetic proteins. Circulation 2001; 104: 790-5.
24. Zhang S, Fantozzi, Tigno DD, et al: Bone morphogenetic proteins induce apoptosis in human pulmonary vascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2003; 285: L740-54.
25. Newman JH, Wheeler L, Lane KB, et al: Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. N Engl J Med 2001; 345: 319-24.
26. Thomson JR, Machado RD, Pauciulo MW, et al: Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGFβ family. J Med Genet 2000; 37: 741-5.
27. Newman JH, Fanburg BL, Archer SL, et al: Pulmonary arterial hypertension: future directions report of an NHLBI/ORD workshop. Circulation 2004; 109: 2947-52.
28. Richter A, Yeager ME, Zaiman A, et al: Impaired transforming growth factor-β signaling in idiopathic pulmonary hypertension. Am J Respir Crit Care Med 2004; 170: 1340-8.
29. Lee SD, Shroyer KR, Markham NE, Cool CD, Voelkel NF, Tuder RM: Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest 1998; 101: 927-34.
30. Fishman AP: Clinical classification of pulmonary hypertension. Clin Chest Med 2001; 22: 385-91.
31. Abenhaim L, Moride Y, Brenot F, et al: Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996; 335: 609-16.
32. Simonneau G, Fartoukh M, Sitbon O, Humbert M, Jagot J-L, Hervé P: Primary pulmonary hypertension associated with the use of fenfluramine derivatives. Chest 1998; 114: 195S-198S.
33. Newmann JH, Trembath RC, Morse JA, et al: Genetic basis of pulmonary arterial hypertension; Current understanding and future directions. J Am Coll Cardiol 2004; 43: 33S-39S.
34. Roberts KE, McElroy JJ, Wong WP, et al: BMPR2 mutations in pulmonary arterial hypertension with congenital heart defects. Eur Respir J 2004; 24: 371-4.
35. Pepper MS: Transforming growth factor beta: vasculogenesis, angiogenesis and vessel wall integrity. Cytokine Growth Factor Rev 1997; 8: 21-43.
36. Shovlin CL, Letarte M: Hereditary hemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms. Thorax 1999; 54: 714-29.
37. Trembath R, Thomson JR, Machado RD, et al: Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2001; 345: 325-34.
38. Abdalla SA, Gallione CJ, Barst RJ, et al: Primary pulmonary hypertension in families with hereditary haemorrhagic telangiectasia. Eur Respir J 2004; 23: 373-7.
39. Harrison RE, Berger R, Haworth SG, et al: Transforming growth factor-β mutations and pulmonary arterial hypertension in childhood. Circulation 2005; 111: 435-41.
40. Chaouat A, Coufet F, Favre C, et al: Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arteial hypertension. Thorax 2004; 59: 446-8.
41. Hervé P, Drouet L, Dosquet C, et al: Primary pulmonary hypertension in a patient with a familial platelet storage pool. Am J Med 1990; 89: 117-20.
42. Hervé P, Launay JM, Scrobohaci ML, et al: Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995; 99: 249-54.
43. Eddahibi S, Humbert M, Fadel E, et al: Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 2001; 108: 1141-50.
44. Eddahibi S, Chaouat A, Morrel N, et al: Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease. Circulation 2003; 108: 1839-44.
45. McGoon M, Gutterman D, Steen V, et al: Screening, early detection and diagnosis of pulmonary arterial hypertension. ACCP Evidence-based clinical practice guidelines. Chest 2004; 126: 14S-34S.
46. Grunig E, Janssen B, Mercles D, et al: Abnormal pulmonary artery pressure response in asymptomatic carriers of primary pulmonary hypertension gene. Circulation 2000; 102: 1145-50.
47. Hall IP: Pharmacogenetics, pharmacogenomics and airway disease. Respir Res 2002; 3: 10.
48. Higenbottam T, Humbert M, Simonneau G, et al: Subjects deficient for CYP2D6 expression (poor metabolisers) are over-represented among patients with anorectic associated pulmonary hypertension. Am J Respir Crit Care Med 1999; 159: A165.
49. Sitbon O, Humbert M, Jais X, et al: Long-term response to calcium-channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; in press.
50. Du L, Sullivan CC, Chu D, et al: Signaling molecules in non familial pulmonary hypertension. N Engl J Med 2003; 348: 500-9.
51. Kido M, Du E, Sullivan CC, Deutsch R, Jamieson SW, Thistlethwaite PA: Gene transfer of a TIE 2 receptor antagonist prevents pulmonary hypertension in rodents. J Thorac Cardiovasc Surg 2005; 129: 268-76.